1. Academic Validation
  2. Discovery of Novel N-(Anthracen-9-ylmethyl) Benzamide Derivatives as ZNF207 Inhibitors Promising in Treating Glioma

Discovery of Novel N-(Anthracen-9-ylmethyl) Benzamide Derivatives as ZNF207 Inhibitors Promising in Treating Glioma

  • J Med Chem. 2024 Feb 20. doi: 10.1021/acs.jmedchem.3c02241.
Menghan Zhang 1 Yushi Ding 2 Mengkang Gao 3 Xiaolin Lu 4 Jun Tan 4 Fei Yu 1 Congying Gu 4 Lujun Gu 1 Xiameng Ren 1 Chenyan Hao 4 Liqin Ming 4 Kang Xu 4 Wenhao Mao 1 Yuqing Jin 1 Min Zhang 2 Linjun You 2 5 Zhanbo Wang 2 5 Yuanyuan Sun 6 Jingwei Jiang 6 Yong Yang 1 7 8 Dayong Zhang 4 Xinying Tang 1
Affiliations

Affiliations

  • 1 School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China 211112.
  • 2 Institute of Pharmaceutical Sciences, China Pharmaceutical University, Nanjing, China 211112.
  • 3 School of Pharmacy, China Pharmaceutical University, Nanjing, China 211112.
  • 4 School of Science, China Pharmaceutical University, Nanjing, China 211112.
  • 5 Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, China 211112.
  • 6 Shuangyun BioMed Sci & Tech (Suzhou) Co., Ltd, Suzhou, China 215000.
  • 7 State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China 211112.
  • 8 School of Pharmacy, Xuzhou Medical University, Xuzhou, China 221004.
Abstract

Targeting tumor stemness is an innovative approach to Cancer treatment. Zinc Finger Protein 207 (ZNF207) is a promising target for weakening the stemness of glioma cells. Here, a series of novel N-(anthracen-9-ylmethyl) benzamide derivatives against ZNF207 were rationally designed and synthesized. The inhibitory activity was evaluated, and their structure-activity relationships were summarized. Among them, C16 exhibited the most potent inhibitory activity, as evidenced by its IC50 values ranging from 0.5-2.5 μM for inhibiting sphere formation and 0.5-15 μM for cytotoxicity. Furthermore, we found that C16 could hinder tumorigenesis and migration and promote Apoptosis in vitro. These effects were attributed to the downregulation of stem-related genes. The in vivo evaluation demonstrated that C16 exhibited efficient permeability across the blood-brain barrier and potent efficacy in both subcutaneous and orthotopic glioma tumor models. Hence, C16 may serve as a potential lead compound targeting ZNF207 and has promising therapeutic potential for glioma.

Figures
Products